293 related articles for article (PubMed ID: 31270220)
1. Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability.
Ford JH; Ayer DW; Zhang Q; Carter JN; Leroux E; Skljarevski V; Aurora SK; Tockhorn-Heidenreich A; Lipton RB
Neurology; 2019 Jul; 93(5):e508-e517. PubMed ID: 31270220
[TBL] [Abstract][Full Text] [Related]
2. Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN).
Ford J; Tassorelli C; Leroux E; Wang S; Ayer D; Nichols R; Detke H
Qual Life Res; 2021 Jan; 30(1):105-115. PubMed ID: 32930994
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
Stauffer VL; Dodick DW; Zhang Q; Carter JN; Ailani J; Conley RR
JAMA Neurol; 2018 Sep; 75(9):1080-1088. PubMed ID: 29813147
[TBL] [Abstract][Full Text] [Related]
4. Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
Popoff E; Johnston K; Croop R; Thiry A; Harris L; Powell L; Coric V; L'Italien G; Moren J
Headache; 2021 Jun; 61(6):906-915. PubMed ID: 34021585
[TBL] [Abstract][Full Text] [Related]
5. Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study.
Ford JH; Stauffer VL; McAllister P; Akkala S; Sexson M; Ayer DW; Wang S
Qual Life Res; 2021 Feb; 30(2):455-464. PubMed ID: 32944843
[TBL] [Abstract][Full Text] [Related]
6. Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials.
Jedynak J; Eross E; Gendolla A; Rettiganti M; Stauffer VL
J Headache Pain; 2021 May; 22(1):48. PubMed ID: 34049484
[TBL] [Abstract][Full Text] [Related]
7. Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.
Ford JH; Kurth T; Starling AJ; Ayer DW; Wietecha LA; Port MD; Rettiganti M; Ruff DD
Headache; 2020 Nov; 60(10):2304-2319. PubMed ID: 33249580
[TBL] [Abstract][Full Text] [Related]
8. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials).
Ailani J; Andrews JS; Rettiganti M; Nicholson RA
J Headache Pain; 2020 Oct; 21(1):123. PubMed ID: 33069214
[TBL] [Abstract][Full Text] [Related]
9. Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States.
Varnado OJ; Ye W; Mi X; Burge R; Hall J
J Med Econ; 2023; 26(1):149-157. PubMed ID: 36601798
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
[TBL] [Abstract][Full Text] [Related]
11. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
Silberstein SD; Stauffer VL; Day KA; Lipsius S; Wilson MC
J Headache Pain; 2019 Jun; 20(1):75. PubMed ID: 31253091
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.
Skljarevski V; Matharu M; Millen BA; Ossipov MH; Kim BK; Yang JY
Cephalalgia; 2018 Jul; 38(8):1442-1454. PubMed ID: 29848108
[TBL] [Abstract][Full Text] [Related]
13. Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials.
Stauffer VL; Wang S; Voulgaropoulos M; Skljarevski V; Kovacik A; Aurora SK
Headache; 2019 Jun; 59(6):834-847. PubMed ID: 30942898
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure.
Ruff DD; Ford JH; Tockhorn-Heidenreich A; Sexson M; Govindan S; Pearlman EM; Wang SJ; Khan A; Aurora SK
Cephalalgia; 2019 Jul; 39(8):931-944. PubMed ID: 31104507
[TBL] [Abstract][Full Text] [Related]
15. 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.
Rosen N; Pearlman E; Ruff D; Day K; Jim Nagy A
Headache; 2018 Oct; 58(9):1347-1357. PubMed ID: 30341990
[TBL] [Abstract][Full Text] [Related]
16. Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER).
Tepper SJ; Ailani J; Ford JH; Nichols RM; Li LQ; Kemmer P; Hand AL; Tockhorn-Heidenreich A
Clin Drug Investig; 2022 Mar; 42(3):263-275. PubMed ID: 35041159
[TBL] [Abstract][Full Text] [Related]
17. Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies.
Detke HC; Millen BA; Zhang Q; Samaan K; Ailani J; Dodick DW; Aurora SK
Headache; 2020 Feb; 60(2):348-359. PubMed ID: 31710104
[TBL] [Abstract][Full Text] [Related]
18. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies.
Förderreuther S; Zhang Q; Stauffer VL; Aurora SK; Láinez MJA
J Headache Pain; 2018 Dec; 19(1):121. PubMed ID: 30594122
[TBL] [Abstract][Full Text] [Related]
19. Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.
Hu B; Li G; Li X; Wu S; Yu T; Li X; Zhao H; Jia Z; Zhuang J; Yu S
J Headache Pain; 2022 Jul; 23(1):90. PubMed ID: 35896988
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials.
Ruff DD; Ford JH; Tockhorn-Heidenreich A; Stauffer VL; Govindan S; Aurora SK; Terwindt GM; Goadsby PJ
Eur J Neurol; 2020 Apr; 27(4):609-618. PubMed ID: 31692188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
